Rosmantuzumab (INN;[1] development code OMP-131R10) is a humanized monoclonal antibody designed for the treatment of cancer.
[2][3][4] This drug was developed by OncoMed Pharmaceuticals.
[5] This monoclonal antibody–related article is a stub.
You can help Wikipedia by expanding it.